alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Parkinson Disease in 10 studies
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, G | 1 |
| Shin, N | 1 |
| Kim, KS | 1 |
| Tamura, H | 1 |
| Sasaki, M | 1 |
| Nakajima, S | 1 |
| Nishio, R | 1 |
| Saeki, N | 1 |
| Katahira, M | 1 |
| Tamano, H | 1 |
| Takeda, A | 1 |
| Pelosi, A | 1 |
| Murray, TK | 1 |
| Whalley, K | 1 |
| Robinson, CS | 1 |
| Ward, MA | 1 |
| Hicks, CA | 1 |
| Lodge, D | 1 |
| Vandergriff, JL | 1 |
| Baumbarger, P | 1 |
| Siuda, E | 1 |
| Gates, M | 1 |
| Ogden, AM | 1 |
| Skolnick, P | 1 |
| Zimmerman, DM | 1 |
| Nisenbaum, ES | 1 |
| Bleakman, D | 1 |
| O'Neill, MJ | 1 |
| Galeffi, F | 1 |
| Bianchi, L | 1 |
| Bolam, JP | 1 |
| Della Corte, L | 1 |
| Calon, F | 1 |
| Rajput, AH | 1 |
| Hornykiewicz, O | 1 |
| Bédard, PJ | 1 |
| Di Paolo, T | 1 |
| Ossowska, K | 1 |
| Luquin, MR | 1 |
| Obeso, JA | 1 |
| Laguna, J | 1 |
| Guillén, J | 1 |
| Martínez-Lage, JM | 1 |
| Klockgether, T | 1 |
| Turski, L | 1 |
| Svensson, TH | 1 |
| Mathé, JM | 1 |
| Nomikos, GG | 1 |
| Schilström, B | 1 |
2 reviews available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Parkinson Disease
| Article | Year |
|---|---|
Cell-specific α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Glutamic Acid; Humans; Parkinson Disease | 2017 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease M | 1994 |
8 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Parkinson Disease
| Article | Year |
|---|---|
Galvanic vestibular stimulation down-regulated NMDA receptors in vestibular nucleus of PD model.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Electric Stimulation; Parkinson D | 2022 |
Reactive oxygen species produced by Zn
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Dopaminergic Neurons; Edema; Hydr | 2023 |
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 2003 |
The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; | 2003 |
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Binding Sites; Bi | 2003 |
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1993 |
Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Basal Ganglia; Cycloleucine; Elec | 1993 |
Role of excitatory amino acids in the ventral tegmental area for central actions of non-competitive NMDA-receptor antagonists and nicotine.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anim | 1998 |